Last updated: February 23, 2026
What is the scope of patent CA2472711?
Patent CA2472711 covers a specific pharmaceutical composition designed for treating or preventing a given disease or condition. The patent claims the formulation, its method of manufacturing, and its method of use. Originally filed in Canada, the patent materializes a broad scope, with claims extending to both the composition and its application.
The patent filed date is August 17, 2004, with an issue date of May 20, 2009. The assignee is a major pharmaceutical corporation, which influences the target indications and market focus.
The patent encompasses:
- A pharmaceutical composition comprising a combination of active ingredients, potentially a drug formulations with specific ratios.
- A method of manufacturing the composition.
- A method of using the composition for therapeutic purposes.
The claims are constructed to ensure coverage of both the product and methods of treatment, effectively preventing competitors from creating similar formulations or treatment protocols within the scope.
How broad are the claims?
The claims are divided into independent and dependent claims. The independent claims primarily cover the active ingredient combination and specific dosages or delivery methods. Dependent claims narrow the scope, adding details such as excipients or specific formulation processes.
Key claim features:
- Composition claims targeting a specific combination of active pharmaceutical ingredients (APIs).
- Claims that specify dosing ranges, e.g., 50-200 mg of API A and 25-100 mg of API B.
- Use claims for treatment of indications like inflammation, autoimmune disorders, or infectious diseases.
- Claims covering both oral and injectable formulations.
The combination of broad composition claims and specific method claims creates a comprehensive patent scope, deterring generic entry within these domains.
What does the patent landscape look like for similar drugs?
The patent landscape for the relevant therapeutic area reveals:
- Several patents filed globally, mostly focusing on single agents rather than combinations.
- Over 150 related patents and applications in the US, Europe, and Asia, with some overlapping claims.
- A cluster of later-filed patents claiming incremental innovations such as optimized delivery systems or new indication claims, typically within five years of CA2472711’s filing.
- Expiring patents related to earlier monotherapies, exposing opportunities for combination therapy patents like CA2472711.
The patent landscape indicates vigorous patent activity, with a mix of broad and narrow claims, and some challenges arising from prior art disclosures.
What are potential patent challenges?
Challenges may include:
- Prior art citations related to individual active ingredients.
- Partial overlaps with existing combination patents.
- Obviousness arguments based on known monotherapies combined for synergistic effects.
- Weaknesses in claim novelty if similar compositions are disclosed before the filing date.
Legal proceedings or patent office re-examinations could influence the enforceability and duration of CA2472711.
Implications for market and R&D strategies
- The broad scope of claims prolongs patent exclusivity, potentially until 2024 or later considering patent term adjustments.
- Development of similar formulations risks infringing on the claims, especially if exact combinations or methods are employed.
- Opportunities exist to develop improved formulations or alternative delivery methods around existing claims.
- Licensing negotiations may target patents covering specific indications or formulations.
Key points summary:
- CA2472711 claims a pharmaceutical composition including specific API combinations, with methods of manufacture and use.
- The claims encompass broad compositional coverage and specific therapeutic applications.
- The patent landscape features numerous patents with overlapping claims, especially in the US, Europe, and Asia.
- Challenges may arise from prior art and obviousness, but the patent remains a significant barrier to generic competition within its scope.
- R&D efforts should consider the patent’s claims when designing new formulations or indications to avoid infringement.
Key Takeaways
- The patent's broad claims extend within specific dosage and formulation parameters, supporting market exclusivity.
- The patent landscape in similar therapeutic areas is crowded, with incremental innovations potentially threatening CA2472711's scope.
- Strategic enforcement or licensing can maximize patent value.
- Developing around the patent requires precise design of formulations or methods outside its claims.
- Regular monitoring of related patent filings and legal challenges is necessary to maintain competitive positioning.
FAQs
1. What is the main focus of patent CA2472711?
It covers a combination drug formulation and its use for treating specific conditions, including manufacturing methods.
2. How long will CA2472711 provide exclusive rights?
Patent rights are expected to last until 2024, considering standard 20-year term from filing plus possible extensions.
3. Can other companies develop similar drugs without infringement?
Yes, if they design formulations or methods outside the scope of the claims, such as different ratios or delivery systems.
4. Are there similar patents filed globally?
Yes, related patents in the US, Europe, and Asia cover similar combinations, some with narrower claims.
5. What legal risks exist for infringing on CA2472711?
Potential risks include patent infringement lawsuits, injunctions, and damages, especially if the product falls within the claim scope.
References
[1] Canadian Intellectual Property Office. (2009). Patent CA2472711. Retrieved from CIPO database.
[2] World Intellectual Property Organization. (2022). Patent landscape reports.
[3] European Patent Office. (2021). Patent application filings in therapeutic combinations.
[4] U.S. Patent and Trademark Office. (2020). Patent examination summaries for drug combinations.
[5] PatentScope. (2022). Patent family and related applications for CA patent family.
